Literature DB >> 31013250

Dabigratan-related acute agranulocytosis.

Ahmad Al-Khaffaf1, Francesco Frattini1, Cinzia Sissa1, Elda Mimiola1, Massimo Franchini1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31013250      PMCID： PMC6476740          DOI： 10.2450/2019.0237-18

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  5 in total

1.  Acute agranulocytosis after oral administration of dabigatran: a rare case report and a short review of literature.

Authors:  Sergio Fasullo; Stefania Davì; Gioacchino Cosenza; Francesca Di Franco; Nicola La Manna; Alfonso Giubilato; Graziella Vetrano; Giorgio Maringhini
Journal:  J Thromb Thrombolysis       Date:  2018-05       Impact factor: 2.300

2.  Position Paper on laboratory testing for patients on direct oral anticoagulants. A Consensus Document from the SISET, FCSA, SIBioC and SIPMeL.

Authors:  Armando Tripodi; Walter Ageno; Marcello Ciaccio; Cristina Legnani; Giuseppe Lippi; Cesare Manotti; Rossella Marcucci; Marco Moia; Benedetto Morelli; Daniela Poli; Agostino Steffan; Sophie Testa
Journal:  Blood Transfus       Date:  2017-09-13       Impact factor: 3.443

3.  The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.

Authors:  Jan Steffel; Peter Verhamme; Tatjana S Potpara; Pierre Albaladejo; Matthias Antz; Lien Desteghe; Karl Georg Haeusler; Jonas Oldgren; Holger Reinecke; Vanessa Roldan-Schilling; Nigel Rowell; Peter Sinnaeve; Ronan Collins; A John Camm; Hein Heidbüchel
Journal:  Eur Heart J       Date:  2018-04-21       Impact factor: 29.983

4.  Use of dabigatran and rivaroxaban in non-valvular atrial fibrillation: one-year follow-up experience in an Italian centre.

Authors:  Mario Schiavoni; Maurizio Margaglione; Antonella Coluccia
Journal:  Blood Transfus       Date:  2017-01-30       Impact factor: 3.443

5.  Agranulocytosis immediately after oral administration of cibenzoline and dabigatran in a patient with paroxysmal atrial fibrillation.

Authors:  Hideki Hayashi; Katsuyuki Kitoh; Kenichi Mitsunami; Minoru Horie
Journal:  Intern Med       Date:  2012-08-01       Impact factor: 1.271
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.